2021
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma.
Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas 2021, 50: 469-493. PMID: 33939658, DOI: 10.1097/mpa.0000000000001792.Peer-Reviewed Original ResearchConceptsUnresectable pheochromocytomaMedical managementNorth American Neuroendocrine Tumor Society Consensus GuidelinesRadiologists/nuclear medicine physiciansNuclear medicine physiciansMedical oncologistsConsensus guidelinesMedicine physiciansConsensus conferenceRadiation oncologistsPheochromocytomaParagangliomaOncologistsSurveillancePanel membersFinal recommendationsLiterature reviewFinal approvalControversial topic
2020
North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19
Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas 2020, 49: 10.1097/mpa.0000000000001561. PMID: 32433264, PMCID: PMC7253037, DOI: 10.1097/mpa.0000000000001561.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusCoronavirus InfectionsCOVID-19Health PersonnelHumansInfectious Disease Transmission, Patient-to-ProfessionalInfectious Disease Transmission, Professional-to-PatientNeuroendocrine TumorsNorth AmericaOccupational DiseasesOccupational ExposurePandemicsPneumonia, ViralSARS-CoV-2Societies, MedicalNANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, Mailman J, Menda Y, Metz DC, Mittra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. Journal Of Nuclear Medicine 2020, 61: 222-227. PMID: 32015164, PMCID: PMC9364765, DOI: 10.2967/jnumed.119.240911.Peer-Reviewed Original ResearchMeSH KeywordsConsensusHumansNeuroendocrine TumorsNuclear MedicineOctreotideOrganometallic CompoundsPatient SelectionReceptors, PeptideSocieties, Medical
2018
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 693-702. PMID: 29891520, DOI: 10.6004/jnccn.2018.0056.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Gland NeoplasmsAdultDelivery of Health Care, IntegratedHumansMedical OncologyNeuroendocrine TumorsSocieties, MedicalUnited StatesConceptsPrimary neuroendocrine tumorNeuroendocrine tumorsAdrenal tumorsManagement of NETsLocoregional advanced diseaseNCCN Guidelines InsightsAdrenal gland tumorsAdvanced diseaseNCCN guidelinesAdult patientsDistant metastasisGastrointestinal tractGland tumorsTumorsNeuroendocrineManagement optionsGuidelinesPatientsPheochromocytomaMetastasisParagangliomaDiseaseTract
2017
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors
Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O’Dorisio T, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas 2017, 46: 707-714. PMID: 28609356, PMCID: PMC5642985, DOI: 10.1097/mpa.0000000000000850.Peer-Reviewed Original ResearchConceptsMidgut neuroendocrine tumorsNeuroendocrine tumorsNorth American Neuroendocrine Tumor Society Consensus GuidelinesNorth American Neuroendocrine Tumor SocietyNETTER-1 trialRADIANT-4 studyRefractory carcinoid syndromePhase 3 studyNonfunctioning neuroendocrine tumorEnteropancreatic neuroendocrine tumorsConsensus-based guidelinesCLARINET trialRADIANT-2Carcinoid syndromeTelotristat ethylMedical managementTherapeutic optionsConsensus guidelinesSurgical guidelinesLu-DOTATATEMultidisciplinary panelProximal colonGastrointestinal tractSmall intestinePatients
2013
Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors
Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. Pancreas 2013, 42: 557-577. PMID: 23591432, PMCID: PMC4304762, DOI: 10.1097/mpa.0b013e31828e34a4.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorHumansMolecular Targeted TherapyNeuroendocrine TumorsNorth AmericaSocieties, MedicalConceptsNeuroendocrine tumorsConsensus guidelinesNorth American Neuroendocrine Tumor SocietyPhase 3 trialTreatment of patientsHeterogeneous clinical presentationPractice-changing outcomesClinical presentationNovel agentsAnatomic locationTumorsHeterogeneous groupDegree of aggressivenessTreatmentDiseaseConsensus tableGuidelinesRigorous evaluationEverolimusSunitinibPatientsMalignancyPhysiciansTrials